US 11,655,242 B2
Glucagon-like peptide1 receptor agonists
David Andrew Coates, New Palestine, IN (US); Todd Fields, New Palestine, IN (US); Joseph Daniel Ho, San Diego, CA (US); and Fucheng Qu, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jun. 19, 2020, as Appl. No. 16/906,063.
Claims priority of provisional application 62/904,906, filed on Sep. 24, 2019.
Claims priority of provisional application 62/868,117, filed on Jun. 28, 2019.
Prior Publication US 2020/0407347 A1, Dec. 31, 2020
Int. Cl. C07D 405/14 (2006.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01)
CPC C07D 405/14 (2013.01) [A61P 3/10 (2018.01); A61K 9/0053 (2013.01)] 18 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
wherein
R1 is H or F;
R2 is H; and
R3 is CH3;
or a pharmaceutically acceptable salt thereof.